Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04699591 · ClinicalTrials.gov registry record · NA

Compassionate Use of Domperidone for Refractory Gastroparesis

A NA study of Gastroparesis and Gastroesophageal Reflux, sponsored by Children's Mercy Hospital Kansas City.

Recruiting
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT04699591 is a NA study of Gastroparesis and Gastroesophageal Reflux that is actively recruiting participants, run by Children's Mercy Hospital Kansas City. The registered enrollment target is 20 participants, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04699591, a NA study of Gastroparesis and Gastroesophageal Reflux, is actively recruiting participants, sponsored by Children's Mercy Hospital Kansas City.

RECRUITING
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

The purpose of this program is to allow the use of domperidone in children from 12 to 21 years of age with symptoms related to motility disorders and Gastroesophageal reflux disease (GERD) who have failed all the standard treatments for their condition.

Interventions

  • DRUG Domperidone

Study Locations (1)

Missouri

  • Children's Mercy Hospitals and Clinics - Kansas City

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2013-04
Est. Completion 2035-12
Phase NA

What the Registry Record Tells You About NCT04699591

The ClinicalTrials.gov registry entry for NCT04699591 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 302-participant average among 44 other Gastroparesis trials with a reported enrollment target (93% lower). The listed sponsor is Children's Mercy Hospital Kansas City, which has 184 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Gastroparesis appearing as the primary indexed condition, and to 1 intervention - of which Domperidone is the first listed.

NCT04699591 reports 1 study location spanning 1 distinct geographic area - top geographies include Missouri.

Frequently Asked Questions

What is clinical trial NCT04699591 about?

NCT04699591 is a clinical study titled "Compassionate Use of Domperidone for Refractory Gastroparesis". The purpose of this program is to allow the use of domperidone in children from 12 to 21 years of age with symptoms related to motility disorders and Gastroesophageal reflux disease (GERD) who have failed all the standard treatments for their condition.

What is the current status of trial NCT04699591?

This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2013-04. Estimated completion is 2035-12.

What conditions does trial NCT04699591 study?

This clinical trial studies the following conditions: Gastroparesis, Gastroesophageal Reflux, GERD.

What interventions are being tested in trial NCT04699591?

The interventions under investigation include: Domperidone (DRUG).

Who is sponsoring clinical trial NCT04699591?

This trial is sponsored by Children's Mercy Hospital Kansas City, which has 184 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04699591 being conducted?

This trial has 1 study location across Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Gastroparesis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.